A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. - Wikidata - wikimedia - TriplyDB

A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.

A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.

http://www.wikidata.org/entity/Q30445071

about

Vaccinia virus L1 binds to cell surfaces and blocks virus entry independently of glycosaminoglycans Structural basis for the binding of the neutralizing antibody, 7D11, to the poxvirus L1 protein The Structure of the Poxvirus A33 Protein Reveals a Dimer of Unique C-Type Lectin-Like Domains Potent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 Protein The mature virion of ectromelia virus, a pathogenic poxvirus, is capable of intrahepatic spread and can serve as a target for delayed therapy.New classes of orthopoxvirus vaccine candidates by functionally screening a synthetic library for protective antigens.Vaccinia virus exhibits cell-type-dependent entry characteristics.Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.ACAM2000: the new smallpox vaccine for United States Strategic National Stockpile.Antibody against extracellular vaccinia virus (EV) protects mice through complement and Fc receptors.Genomic expression libraries for the identification of cross-reactive orthopoxvirus antigens.A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.Poxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein.The myristate moiety and amino terminus of vaccinia virus l1 constitute a bipartite functional region needed for entry Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.TLR3 and TLR9 agonists improve postexposure vaccination efficacy of live smallpox vaccines.Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin Enhancement of protein vaccine potency by in vivo electroporation mediated intramuscular injection.Smallpox vaccines: targets of protective immunity.Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.Immunization with a vaccine combining herpes simplex virus 2 (HSV-2) glycoprotein C (gC) and gD subunits improves the protection of dorsal root ganglia in mice and reduces the frequency of recurrent vaginal shedding of HSV-2 DNA in guinea pigs compa Polyclonal antibody cocktails generated using DNA vaccine technology protect in murine models of orthopoxvirus disease.Smallpox subunit vaccine produced in Planta confers protection in mice.Bioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model for human smallpox Major neutralizing sites on vaccinia virus glycoprotein B5 are exposed differently on variola virus ortholog B6 Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens Adsorption of recombinant poxvirus L1-protein to aluminum hydroxide/CpG vaccine adjuvants enhances immune responses and protection of mice from vaccinia virus challenge Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge The orthopoxvirus type I IFN binding protein is essential for virulence and an effective target for vaccination Disparity between levels of in vitro neutralization of vaccinia virus by antibody to the A27 protein and protection of mice against intranasal challenge.Improving vaccines by incorporating immunological coadjuvants.Immunostimulatory DNA as a vaccine adjuvant.Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines.Active vaccination with vaccinia virus A33 protects mice against lethal vaccinia and ectromelia viruses but not against cowpoxvirus; elucidation of the specific adaptive immune response.Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.Smallpox vaccines for biodefense.Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine

P2860

Q27488704-B1B4DE5B-7FCB-4191-837E-0BF4AE013F59 Q27647102-5FEDA547-D8AE-4F29-9021-CFFE213C4125 Q27658759-3B3E6007-1136-40E1-BE85-E409D89BF61C Q27684713-AF0AE82A-4176-49BF-8D51-CF0AF393EE50 Q30223108-31CF0C09-DFFF-441A-9135-C08AF4E2C4F1 Q33508318-E7323860-6153-4542-9A0A-718CC0F65A22 Q33698769-4CF3A4F2-0DDD-48D7-94D9-6CDE2FFA5808 Q33725635-87585A60-4BC7-4751-ADC9-6C4D8E484EED Q33892570-50E41D09-2764-4FEA-82A1-D83549F72940 Q33936717-2C798282-EFDA-4078-B10A-4B28C2923FC9 Q33968161-9810D671-0A25-4698-AC8C-E02CA378827D Q34126697-C05E3515-AC63-4390-91A2-5EA64AB117ED Q34190609-3EFB52CC-5AD9-4543-A448-6A476597CC87 Q34259469-9C5F0395-766E-48F5-BB1F-B83979B1ADC7 Q34289866-025C1E28-A6B4-4B79-ACAD-4614297E2D95 Q34414790-97B890C1-B82F-4BE2-9237-D439F2AFE9D2 Q34484027-3F3AA05F-6ACF-4199-BE55-B4064A9ABF7C Q34516610-B5C46D3B-F79F-4CD7-A6C9-3B20E6417C5B Q34780607-7AEAC2A7-212C-40A5-A0F1-DB6BB74C1FE5 Q35226200-0E0875AE-50D0-4AB3-B49D-9B3197901DCD Q35275146-A379FC3E-CDED-4CD2-BBC7-FF95A23C317F Q35339702-92EF2AFA-18A9-43BD-A026-B00F657E403B Q35800424-F56E97D6-C282-4289-AF1A-444F4E1007EC Q35909727-64757C9A-24ED-4DC1-964D-DFA12AD1BE68 Q35947572-865C2BD9-447E-45CD-A146-449E336F8248 Q35948047-F8754ED0-2920-4596-875D-1E4045F281D0 Q36477717-97675862-58EF-4C70-8893-869A70DF2F31 Q36487366-A9E026E6-F839-4F93-AFC4-88DCA77C361A Q36498244-EF07B348-8642-42F6-87C5-9DBDA7CDCA84 Q36537978-815C0294-B460-42DA-B745-0CEED0895156 Q36845650-35075732-7FA8-44B8-96D2-EC08991C96D1 Q36899084-9A394EAC-CCF8-4EF0-BA25-7EF7FD832BD9 Q36968274-211CD321-535A-44C8-B6CC-8069E18D3555 Q37003207-5D232BE2-5667-4CA8-8923-769BBE8A6BFC Q37042331-8D0B4D12-5ED3-4E94-B6B6-9DF5263E953D Q37051617-ADDDB4FB-696B-450D-957B-A8AF7EC63BF0 Q37125302-FC1607F2-2B28-406B-8FF3-F74CFDDDADD2 Q37169163-57420617-D317-482D-990A-3420A1C47D26 Q37393765-775A9F27-8B98-4F42-8D4A-FBAD4DDB9734 Q37439603-816B6CCD-8FE9-4672-9649-EBBA95429580

P2860

A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost.

http://www.wikidata.org/entity/Q30445071

description

2006 nî lūn-bûn

@nan

2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A protein-based smallpox vacci ...... n as a prime and single boost.

@ast

A protein-based smallpox vacci ...... n as a prime and single boost.

@en

type

label

A protein-based smallpox vacci ...... n as a prime and single boost.

@ast

A protein-based smallpox vacci ...... n as a prime and single boost.

@en

prefLabel

A protein-based smallpox vacci ...... n as a prime and single boost.

@ast

A protein-based smallpox vacci ...... n as a prime and single boost.

@en

P1433

Q30445071-98D927AE-BAC5-41CF-B25A-21AAF5A5C480

P1476

Q30445071-3CA89B4A-72EB-4145-A6A4-2F80A1059701

P2093

Q30445071-0D5C4C14-C1A6-4803-A680-351C26F2F1AB

Q30445071-8A2147B2-D88A-4685-B609-825BAE4B99B1

Q30445071-8CB519BB-8DCD-4BE5-9174-DFB82E845B27

Q30445071-98B761E7-C646-4DC5-9C01-EC17902810D2

Q30445071-9CC1D629-698E-4CD8-B1B6-99D561820E9E

Q30445071-9E3C1498-76CA-423A-B3C8-856F2EF75F03

Q30445071-A162F0B8-F6B3-42FC-A705-9E64A5C3C216

Q30445071-CBFC8F5D-791D-424E-90E9-B066B39017F9

Q30445071-F775CF81-93B5-42D4-9ABF-CDE300B89A3B

P2860

Q30445071-0430266D-42C1-44E9-9317-C9B14BF1C60C

Q30445071-07A86CEF-49D5-4DDA-A405-2B894FC39C05

Q30445071-200CEA58-A1A5-4368-A675-BBA2A6EC1BE2

Q30445071-2AC84DC7-A4E1-41D8-BE35-02F39F298094

Q30445071-2AEDE1B3-E7A5-40B1-B1D6-E173EBCF69F9

Q30445071-351A3FC6-4DD1-4577-804E-F86F683C0EA1

Q30445071-422FBB29-E457-42C8-B747-9CAEDDED6D09

Q30445071-497C34A0-35EF-476A-A57A-522DEDC179A6

Q30445071-4C68C7AC-B274-452B-B6F8-CC98863AF87F

Q30445071-4F71E4F6-70E1-4E3C-A6AB-3E1EF5CD0592

P304

Q30445071-73D5468E-0F25-47A4-BCC9-85C0179F7229

P31

Q30445071-9DCF9BAF-B2DE-4967-89B9-A6C3625FFB4B

P356

Q30445071-DE4F797B-5E82-4E30-8ADB-E69E911289DC

P407

Q30445071-1141F20C-BD78-4B47-AFFF-B700923B072A

P433

Q30445071-A5A18808-0807-4076-97E3-3C6C0AFA73D7

P478

Q30445071-38370A73-48AC-4BEE-BF00-545A646305FB

P50

Q30445071-167CA6A2-6B01-4E44-9C95-5D30C24413FA

Q30445071-DF4AD73E-DC34-4251-92D3-BE171E66C7B3

P577

Q30445071-4175594D-2A81-49CC-9F13-D6967930B989

P5875

Q30445071-818A451F-E5DF-4319-90D2-C9058F9149F7

P698

Q30445071-555F46A4-90C9-4B9C-A8DF-E115D2F1A99D

P921

Q30445071-B8B1B289-18E9-4ADC-85A7-E72FD1A82412

P932

Q30445071-66A63957-9158-480A-B9AF-B152080B321B

P356

J.VACCINE.2006.10.009

P1433

P1476

A protein-based smallpox vacci ...... n as a prime and single boost.

@en

P2093

Alexandra M Ortiz

http://www.w3.org/2001/XMLSchema#string

Edward Alexander

http://www.w3.org/2001/XMLSchema#string

Gary H Cohen

http://www.w3.org/2001/XMLSchema#string

Heather L Davis

http://www.w3.org/2001/XMLSchema#string

Huan Lou

http://www.w3.org/2001/XMLSchema#string

J Charles Whitbeck

http://www.w3.org/2001/XMLSchema#string

Lydia Aldaz-Carroll

http://www.w3.org/2001/XMLSchema#string

Stuart N Isaacs

http://www.w3.org/2001/XMLSchema#string

Yuhong Xiao

http://www.w3.org/2001/XMLSchema#string

P2860

Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox

Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.

Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus.

The 1.51-Angstrom structure of the poxvirus L1 protein, a target of potent neutralizing antibodies.

Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.

The formation and function of extracellular enveloped vaccinia virus.

LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox

A model for a smallpox-vaccination policy.

Smallpox vaccination: a review, part II. Adverse events.

Extracellular vaccinia virus envelope glycoprotein encoded by the A33R gene

P304

1214-1224

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.VACCINE.2006.10.009

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Roselyn J. Eisenberg

Thomas J Braciale

P577

2006-10-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6699798

http://www.w3.org/2001/XMLSchema#string

P698

17098336

http://www.w3.org/2001/XMLSchema#string

P921

P932

1857298

http://www.w3.org/2001/XMLSchema#string